Expansion of gammadelta T Cells in patients infected with cutaneous leishmaniasis with and without glucantime therapy.
The expansion of gammadelta T cells in patients with active cutaneous leishmaniasis, with or without glucantime therapy, was investigated. Twenty patients with local cutaneous leishmaniasis including glucantime-treated (n=10) and untreated (n=10) patients were selected. The controls were healthy individuals (n=10) living in endemic areas. Whole blood was obtained and the T cell subpopulations were analyzed by flow cytometry. Significantly more gammadelta CD(3)(+) T cells were observed in untreated patients (15.9% +/-5.9), when compared with glucantime-treated patients (4.6% +/-1.4) and controls (5.3% +/-2.3). On the other hand, when the percentages of alphabeta CD(3)(+) T-cells were analyzed different results were obtained. A significant increase in alphabeta T cells was seen in glucantime-treated patients (62.4% +/-7.6), when compared to the untreated patients (55.7% +/-5.5) and controls (55.1% +/-9.6). The percentage of total CD(3)(+) T cells was statistically greater in both glucantime-treated (68.8% +/-7.4) and untreated patients (73.4% +/-5.9) when compared to the controls (61% +/-10.3). These results are consistent with previous results on the expansion of gammadelta T cells during the course of cutaneous leishmaniasis. They also indicate that glucantime therapy can reverse the expansion of gammadelta T cells and as a result increase the percentages of alphabeta ab CD(3)(+) T cells.
Darabi
Haideh
H
Deptartment of Immunology, Pasteur Institute of Iran, Tehran 13164, IRAN. hdarabi@institute.pasteur.ac.ir
Abolhassani
Mohsen
M
Kariminia
Amina
A
Alimohammadian
Mohammad H
MH
D000328:Adult; D000368:Aged; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate